Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2020 | 470 | 1.750 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2017 | 196 | 1.010 |
Why?
|
| Thoracotomy | 4 | 2016 | 21 | 0.740 |
Why?
|
| Pneumonectomy | 5 | 2020 | 53 | 0.690 |
Why?
|
| Esophageal Neoplasms | 3 | 2015 | 36 | 0.590 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2020 | 15 | 0.540 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 122 | 0.540 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 21 | 0.510 |
Why?
|
| Biomarkers, Tumor | 5 | 2015 | 165 | 0.500 |
Why?
|
| Esophagectomy | 2 | 2011 | 15 | 0.450 |
Why?
|
| Barrett Esophagus | 4 | 2015 | 15 | 0.450 |
Why?
|
| Catheter Ablation | 4 | 2015 | 56 | 0.430 |
Why?
|
| Aged | 26 | 2019 | 7669 | 0.400 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 4 | 0.370 |
Why?
|
| Jejunostomy | 1 | 2011 | 8 | 0.360 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 53 | 0.350 |
Why?
|
| Male | 29 | 2019 | 12453 | 0.340 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2016 | 7 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 175 | 0.340 |
Why?
|
| Female | 30 | 2019 | 12677 | 0.330 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 307 | 0.320 |
Why?
|
| Empyema, Pleural | 1 | 2009 | 1 | 0.310 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2009 | 4 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 54 | 0.310 |
Why?
|
| Postoperative Complications | 4 | 2016 | 819 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 85 | 0.290 |
Why?
|
| Positron-Emission Tomography | 3 | 2011 | 72 | 0.290 |
Why?
|
| Echinocandins | 3 | 2012 | 6 | 0.280 |
Why?
|
| Drainage | 2 | 2009 | 38 | 0.280 |
Why?
|
| Toxicity Tests | 4 | 2016 | 9 | 0.270 |
Why?
|
| Humans | 32 | 2020 | 22848 | 0.270 |
Why?
|
| Middle Aged | 20 | 2017 | 7555 | 0.260 |
Why?
|
| Retrospective Studies | 11 | 2017 | 3062 | 0.250 |
Why?
|
| Embryonic Development | 3 | 2016 | 7 | 0.250 |
Why?
|
| Embryo, Mammalian | 2 | 2016 | 22 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 155 | 0.220 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 11 | 0.220 |
Why?
|
| Prognosis | 6 | 2017 | 630 | 0.210 |
Why?
|
| Aged, 80 and over | 12 | 2017 | 4055 | 0.210 |
Why?
|
| Bronchoscopy | 3 | 2019 | 30 | 0.210 |
Why?
|
| Pleurodesis | 1 | 2003 | 1 | 0.210 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 4 | 0.210 |
Why?
|
| Consensus | 2 | 2020 | 82 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2017 | 2960 | 0.190 |
Why?
|
| Radiosurgery | 3 | 2011 | 33 | 0.190 |
Why?
|
| Antifungal Agents | 2 | 2012 | 39 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2017 | 210 | 0.180 |
Why?
|
| Simulation Training | 1 | 2020 | 31 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2017 | 1621 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 66 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2020 | 160 | 0.160 |
Why?
|
| Surgeons | 1 | 2020 | 80 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 5 | 0.160 |
Why?
|
| False Positive Reactions | 1 | 2019 | 31 | 0.160 |
Why?
|
| Fetal Development | 2 | 2016 | 3 | 0.150 |
Why?
|
| Registries | 4 | 2015 | 166 | 0.150 |
Why?
|
| Fetus | 2 | 2016 | 23 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2017 | 485 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 24 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 279 | 0.140 |
Why?
|
| Bone and Bones | 2 | 2016 | 109 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2020 | 184 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 274 | 0.140 |
Why?
|
| Tracheomalacia | 1 | 2017 | 3 | 0.140 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 4 | 0.140 |
Why?
|
| Silicones | 1 | 2017 | 8 | 0.140 |
Why?
|
| Airway Obstruction | 1 | 2017 | 17 | 0.140 |
Why?
|
| Stents | 1 | 2017 | 41 | 0.130 |
Why?
|
| Disease Progression | 4 | 2014 | 554 | 0.130 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 1 | 0.130 |
Why?
|
| Teratogens | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 6 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 48 | 0.130 |
Why?
|
| Animals | 8 | 2016 | 3025 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 401 | 0.130 |
Why?
|
| Models, Animal | 1 | 2016 | 96 | 0.130 |
Why?
|
| Developmental Biology | 1 | 2016 | 1 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2016 | 9 | 0.130 |
Why?
|
| Ribs | 1 | 2016 | 13 | 0.130 |
Why?
|
| Metformin | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 27 | 0.130 |
Why?
|
| Rats | 5 | 2016 | 554 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 73 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2015 | 14 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 167 | 0.120 |
Why?
|
| Learning Curve | 1 | 2015 | 17 | 0.120 |
Why?
|
| Thoracoscopy | 2 | 2019 | 19 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 8 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2010 | 21 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 135 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 478 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 125 | 0.110 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 83 | 0.110 |
Why?
|
| Research Design | 2 | 2012 | 147 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 7 | 0.100 |
Why?
|
| Adult | 8 | 2017 | 6584 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 7 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 377 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 287 | 0.100 |
Why?
|
| Fundoplication | 1 | 2012 | 19 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 29 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 26 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 588 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 259 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 11 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 15 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 138 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2012 | 28 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 22 | 0.090 |
Why?
|
| Fistula | 1 | 2011 | 1 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 2 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 7 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2011 | 40 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2015 | 1528 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 13 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 12 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2011 | 42 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 14 | 0.090 |
Why?
|
| Risk Factors | 5 | 2015 | 1942 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 305 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 39 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 31 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 64 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 18 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 18 | 0.090 |
Why?
|
| Age Factors | 2 | 2009 | 657 | 0.080 |
Why?
|
| Bronchi | 1 | 2010 | 9 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 157 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 177 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 4 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 150 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 35 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 12 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 70 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 101 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 270 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2014 | 55 | 0.080 |
Why?
|
| United States | 4 | 2015 | 1726 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 400 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 71 | 0.080 |
Why?
|
| Neoplasms | 1 | 2011 | 205 | 0.080 |
Why?
|
| Recurrence | 2 | 2014 | 262 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 137 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2012 | 33 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 162 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 77 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 1220 | 0.070 |
Why?
|
| Rabbits | 2 | 2016 | 166 | 0.060 |
Why?
|
| Lung | 2 | 2005 | 142 | 0.060 |
Why?
|
| Pregnancy | 3 | 2012 | 303 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 280 | 0.060 |
Why?
|
| Pneumonia | 2 | 2019 | 63 | 0.060 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 320 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1494 | 0.050 |
Why?
|
| ROC Curve | 2 | 2014 | 121 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 558 | 0.050 |
Why?
|
| Brain | 1 | 2011 | 1324 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 20 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 649 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 9 | 0.050 |
Why?
|
| Sex Factors | 2 | 2012 | 381 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 846 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 549 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 1721 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 86 | 0.040 |
Why?
|
| Dilatation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 13 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 12 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2016 | 22 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 83 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 49 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 300 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 13 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 22 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 110 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 270 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 50 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 70 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 101 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 453 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 4 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 205 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 241 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 211 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 12 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 20 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 60 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 41 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2012 | 1 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 81 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 146 | 0.020 |
Why?
|
| Voriconazole | 1 | 2012 | 10 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 20 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 28 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 25 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 32 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 29 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 82 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 116 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 3 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 45 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 21 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 80 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 96 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 24 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 15 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 66 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 54 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 45 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 96 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 6 | 0.020 |
Why?
|
| Organogenesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 20 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 12 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 76 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 272 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 354 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 97 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 239 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 1128 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 64 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 30 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 107 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 254 | 0.010 |
Why?
|
| Cognition | 1 | 2011 | 1104 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1290 | 0.010 |
Why?
|